BioCentury
ARTICLE | Company News

Management tracks: Agios, Radius

September 5, 2018 12:07 AM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Schenkein will be succeeded by Jacqualyn Fouse, who is a member of the board. Fouse departed Celgene Corp. (NASDAQ:CELG) in December as president and COO.

In 2010, Celgene paid Agios $130 million up front and took an undisclosed equity stake in return for an exclusive option to license and develop any or all cancer compounds emerging from Agios’ cancer metabolome work. The partners now market isocitrate dehydrogenase 2 (IDH2) inhibitor Idhifa enasidenib in the U.S. to treat relapsed or refractory acute myelogenous leukemia (AML) in adults with an IDH2 mutation (see "Agios' Acceleration")...